227. オスラー病 Osler disease Clinical trials / Disease details

臨床試験数 : 54 / 薬物数 : 73 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136

16 trials found

diseases per page:

Showing 1 to 10 of 16 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100043253	2021-02-17	2021-02-09	The study of genotype analysis of HHT patients in china and clinical efficacy study of bevacizumabin ...	The study of genotype analysis of HHT patients in china and clinical efficacy study of bevacizumabin ...	hereditary hemorrhagic telangiectasia	Trial group:Bevacizumab;	Shandong Provincial ENT Hospital	NULL	Recruiting	16	75	Both	Trial group:30;	Phase 4	China
2	NCT04404881 (ClinicalTrials.gov)	November 23, 2020	22/5/2020	Bevacizumab In Hereditary Hemorrhagic Telangiectasia	A Phase 2 Study of Bevacizumabfor Chronic Bleeding and Iron Deficiency Anemia in Hereditary Hemorrha ...	Hereditary Hemorrhagic Telangiectasia	Drug: Bevacizumab	Hanny Al-Samkari, MD	NULL	Recruiting	18 Years	N/A	All	20	Phase 2	United States
3	NCT03227263 (ClinicalTrials.gov)	September 28, 2017	21/7/2017	BABH Study: Efficacy and Safety of Bevacizumabon Severe Bleedings Associated With Hemorrhagic Heredi ...	BABH Study: Efficacy and Safety of Bevacizumabon Severe Bleedings Associated With Hemorrhagic Heredi ...	Rendu Osler Disease;Telangiectasia, Hereditary Hemorrhagic	Drug: Bevacizumab;Drug: sodium chloride 0.9%	Hospices Civils de Lyon	NULL	Completed	18 Years	N/A	All	24	Phase 3	France
4	EUCTR2017-001031-39-FR (EUCTR)	19/05/2017	19/06/2020	BABH Study: Efficacy and safety of bevacizumabon severe bleedings associated with Hemorrhagic Heredi ...	BABH Study: Efficacy and safety of bevacizumabon severe bleedings associated with Hemorrhagic Heredi ...	Hemorrhagic Hereditary Telangiectasia MedDRA version: 20.0;Level: LLT;Classification code 10031132;T ...	Trade Name: AVASTIN Product Name: BEVACIZUMAB INN or Proposed INN: BEVACIZUMAB	Hospices Civils de Lyon	NULL	Not Recruiting			Female: yes Male: yes	24	Phase 3	France
5	NCT02157987 (ClinicalTrials.gov)	December 15, 2014	4/6/2014	Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab: Se ...	Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab: Se ...	Telangiectasia, Hereditary Hemorrhagic	Drug: bevacuzimab spray	University Hospital, Caen	NULL	Recruiting	18 Years	70 Years	All	30	Phase 1/Phase 2	France
6	NCT02389959 (ClinicalTrials.gov)	August 4, 2014	11/3/2015	Intranasal Bevacizumab for HHT-Related Epistaxis	Intranasal Bevacizumab for HHT-Related Epistaxis	HHT;Hereditary Hemorrhagic Telangiectasia;Epistaxis;Nose Bleeds;Nasal Bleeding	Drug: Bevacizumab;Drug: Placebo (Saline)	Stanford University	NULL	Completed	18 Years	N/A	All	40	Phase 4	United States
7	NCT02106520 (ClinicalTrials.gov)	April 2014	1/4/2014	Efficacy of a BevacizumabNasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangie ...	Efficacy of a BevacizumabNasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangie ...	Hereditary Hemorrhagic Telangiectasia;Epistaxis	Drug: Bevacizumab;Drug: placebo	Hospices Civils de Lyon	NULL	Terminated	18 Years	N/A	Both	80	Phase 2/Phase 3	France
8	EUCTR2013-004204-19-FR (EUCTR)	26/02/2014	16/06/2015	Efficacité du bevacizumaben spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Os ...	Efficacité du bevacizumaben spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Os ...	Rendu-Osler disease MedDRA version: 18.0;Level: LLT;Classification code 10031132;Term: Osler-Weber-R ...	Trade Name: Avastin Product Name: Avastin INN or Proposed INN: BEVACIZUMAB	Hospices Civils de Lyon	NULL	Not Recruiting			Female: yes Male: yes			France
9	NCT01507480 (ClinicalTrials.gov)	October 2011	6/12/2011	The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of BevacizumabNasal Spray to Treat Epist ...	The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of BevacizumabNasal Spray to Treat Epist ...	Rendu Osler Disease;Telangiectasia, Hereditary Hemorrhagic	Drug: Bevacizumab	Hospices Civils de Lyon	NULL	Completed	18 Years	N/A	All	42	Phase 1	France
10	NCT01408030 (ClinicalTrials.gov)	August 2011	1/8/2011	North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)	North American Study of Epistaxis in HHT (NOSE)	Telangiectasia, Hereditary Hemorrhagic;Epistaxis	Drug: Sterile saline;Drug: Bevacizumab;Drug: Estriol;Drug: Tranexamic Acid	James Gossage	HHT Foundation International	Completed	18 Years	N/A	All	123	Phase 2	United States

First Previous1 2Next Last